Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of smac/DIABLO from the mitochondria

[1]  J. Houghton,et al.  Shared pathways: Death receptors and cytotoxic drugs in cancer therapy , 2009, Pathology Oncology Research.

[2]  M. Li‐Weber,et al.  Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL , 2005, Hepatology.

[3]  Wei Guo,et al.  Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors , 2005, Oncogene.

[4]  E. Gelmann,et al.  The ubiquitin-proteasome pathway and its role in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Dinney,et al.  Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. , 2005, Cancer research.

[6]  Wei Guo,et al.  Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation , 2005, Cancer biology & therapy.

[7]  Y. Yen,et al.  Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma , 2005, Molecular Cancer Therapeutics.

[8]  K. Anderson,et al.  Proteasome inhibitor therapy in multiple myeloma , 2005, Molecular Cancer Therapeutics.

[9]  A. Kraft,et al.  The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim , 2005, Molecular Cancer Therapeutics.

[10]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[11]  P. Kloetzel,et al.  The proteasome and MHC class I antigen processing. , 2004, Biochimica et biophysica acta.

[12]  N. Munshi,et al.  Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. , 2004, Blood.

[13]  N. Guseva,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Mediated Activation of Mitochondria-Associated Nuclear Factor-κB in Prostatic Carcinoma Cell Lines11NIH grant CA93870 (M.B. Cohen). , 2004 .

[14]  Seamus J. Martin,et al.  Smac/Diablo Antagonizes Ubiquitin Ligase Activity of Inhibitor of Apoptosis Proteins* , 2004, Journal of Biological Chemistry.

[15]  Zhijian J. Chen,et al.  The novel functions of ubiquitination in signaling. , 2004, Current opinion in cell biology.

[16]  L. Sistonen,et al.  The ubiquitin‐proteasome pathway , 2004, Annals of medicine.

[17]  D. Fang,et al.  Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. , 2004, World journal of gastroenterology.

[18]  N. Guseva,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines. , 2004, Molecular cancer research : MCR.

[19]  B. Aggarwal,et al.  Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. , 2004, Vitamins and hormones.

[20]  J. Houghton,et al.  Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. , 2003, Cancer research.

[21]  W. Zong,et al.  The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells , 2003, Oncogene.

[22]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[23]  J. Houghton,et al.  A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells , 2003, Cell Death and Differentiation.

[24]  E. Bröcker,et al.  Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation , 2003, Molecular and Cellular Biology.

[25]  A. Martelli,et al.  Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation , 2003, Leukemia.

[26]  Michelle S. Johnson,et al.  2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. , 2003, Cancer research.

[27]  J. Berenson,et al.  The role of nuclear factor-?b in the biology and treatment of multiple myeloma , 2001 .

[28]  S. Alkan,et al.  Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis , 2001 .

[29]  P. Hersey,et al.  The Role of NF-κB in TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Melanoma Cells1 , 2001, The Journal of Immunology.

[30]  S. Alkan,et al.  Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. , 2001, British journal of haematology.

[31]  J. Houghton,et al.  Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[33]  P. Schneider,et al.  Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. , 2000, Methods in enzymology.

[34]  I. Herr,et al.  Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .

[35]  A. Harris,et al.  The ubiquitin-proteasome pathway in cancer. , 1998, British Journal of Cancer.